A study of AK002 in patients with fibrotic disease.

Trial Profile

A study of AK002 in patients with fibrotic disease.

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2016

At a glance

  • Drugs AK 002 (Primary)
  • Indications Fibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Oct 2016 New trial record
    • 26 Sep 2016 According to an Allakos media release, company plans to initiate this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top